Comparison of patients who underwent autograft conditioned with high-dose melphalan or busulphan and cyclophosphamide: group 2, idarubicin
| . | Mel n = 72 . | BU/CY n = 15 . | Total DFS, % n = 94 . | Mel DFS, % . | BU/CY DFS, % . | P, Mel vs BU/CY . |
|---|---|---|---|---|---|---|
| French-American-British | ||||||
| M0 | — | — | — | — | — | |
| M1 | 8 | 3 | 42 | 50 | 33 | .52 |
| M2 | 18 | 6 | 48 | 45 | 50 | .90 |
| M3 | 9 | 0 | 76 | 76 | — | — |
| M4 | 14 | 3 | 47 | 25 | 67 | .87 |
| M4Eo | 1* | — | 0 | — | — | — |
| M5 | 2 | 2 | 60 | 62 | 0 | .06 |
| M6 | 0 | 0 | 0 | 0 | — | — |
| M7 | 0 | 0 | 75 | 75 | — | — |
| Age, y | ||||||
| 0-5 | 37 | 5 | 49 | 51 | 20 | .08 |
| 6-10 | 20 | 5 | 58 | 49 | 60 | .89 |
| 11-15 | 15 | 5 | 57 | 37 | 60 | .87 |
| Central nervous system disease | ||||||
| No | 68 | 14 | 51 | 44 | 43 | .39 |
| Yes | 4 | 1 | 100 | 100 | 100 | — |
| Cytogenetics | ||||||
| Good | 18 | 5 | 54 | 52 | 80 | .18 |
| Poor | 14 | 2 | 50 | 50 | 50 | .86 |
| Standard | 34 | 7 | 52 | 55 | 29 | .06 |
| . | Mel n = 72 . | BU/CY n = 15 . | Total DFS, % n = 94 . | Mel DFS, % . | BU/CY DFS, % . | P, Mel vs BU/CY . |
|---|---|---|---|---|---|---|
| French-American-British | ||||||
| M0 | — | — | — | — | — | |
| M1 | 8 | 3 | 42 | 50 | 33 | .52 |
| M2 | 18 | 6 | 48 | 45 | 50 | .90 |
| M3 | 9 | 0 | 76 | 76 | — | — |
| M4 | 14 | 3 | 47 | 25 | 67 | .87 |
| M4Eo | 1* | — | 0 | — | — | — |
| M5 | 2 | 2 | 60 | 62 | 0 | .06 |
| M6 | 0 | 0 | 0 | 0 | — | — |
| M7 | 0 | 0 | 75 | 75 | — | — |
| Age, y | ||||||
| 0-5 | 37 | 5 | 49 | 51 | 20 | .08 |
| 6-10 | 20 | 5 | 58 | 49 | 60 | .89 |
| 11-15 | 15 | 5 | 57 | 37 | 60 | .87 |
| Central nervous system disease | ||||||
| No | 68 | 14 | 51 | 44 | 43 | .39 |
| Yes | 4 | 1 | 100 | 100 | 100 | — |
| Cytogenetics | ||||||
| Good | 18 | 5 | 54 | 52 | 80 | .18 |
| Poor | 14 | 2 | 50 | 50 | 50 | .86 |
| Standard | 34 | 7 | 52 | 55 | 29 | .06 |
Cytogenetics results were available for 86 of 94 group 2 patients. Ten patients received conditioning other than Mel or BU/CY. See “Results” for outcomes.